@article{ff0de377b14348649e76482de96b142a,
title = "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis",
keywords = "DOUBLE-BLIND, MULTICENTER TRIAL, CANCER-RISK, CD20, DEMYELINATION, PATHOLOGY, ANTIBODY, DAMAGE",
author = "X. Montalban and Hauser, {S. L.} and L. Kappos and Arnold, {D. L.} and A. Bar-Or and G. Comi and {de Seze}, J. and G. Giovannoni and Hartung, {H. -P.} and B. Hemmer and F. Lublin and Rammohan, {K. W.} and K. Selmaj and A. Traboulsee and A. Sauter and D. Masterman and P. Fontoura and S. Belachew and H. Garren and N. Mairon and P. Chin and {ORATORIO Clinical Investigators} and Raymond Hupperts and Wolinsky, {J. S.}",
year = "2017",
month = jan,
day = "19",
doi = "10.1056/NEJMoa1606468",
language = "English",
volume = "376",
pages = "209--220",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "MASSACHUSETTS MEDICAL SOCIETY",
number = "3",
}